iOncologi, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of intractable solid tumors. 

We develop next-generation RNA-based immunotherapies that reprogram and mobilize the immune system to overcome the barriers that have historically limited cancer treatment, including immune suppression, tumor heterogeneity, and the blood–brain barrier.

Our integrated platform combines advanced therapeutic design, precision lipid nanoparticle delivery systems, and AI-driven discovery models to accelerate the identification of novel targets and to generate both universal and personalized treatment formulations. These multidisciplinary capabilities enable us to create therapies tailored to each patient’s unique tumor biology—while maintaining scalability, reproducibility, and speed to clinic.

Driven by a commitment to patients with the highest unmet medical needs, iOncologi is advancing a growing pipeline of proprietary therapeutic platforms, supported by strategic collaborations with global leaders in AI, drug development, and translational oncology. With an experienced team of scientists, clinicians, and industry leaders, we are redefining what’s possible in cancer care—delivering adaptable, durable, and life-changing therapies to patients who need them most.


iOncologi

Org chart

Teams

Offices

iOncologi

Org chart

Teams

Offices

Related companies